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ABSTRACT: The long-acting Pi-agonlst salmeterol inhibits in vitro the release of 
inflammatory mediators up to 20 h. These mediators are involved in ultrasonically 
nebulized distilled water (UNDW)-induced bronchoconstriction. We investigated 
whether salmeterol provides prolonged protection against UNDW provocation and 
whether this effect was paralleled by its bronchodilator effects.
Nineteen asthmatic patients (mean forced expiratory volume in one second (FEVi) 
84,8% predicted, mean provocative concentration of histamine producing a 20% 
decrease in FEVi 0.65 mg^mL*1) participated in this randomized, double-blind, 
placebo-controlled crossover trial. After measuring baseline FEVi, patients inhaled 
50 }Ag salmeterol or placebo by metered-dose inhaler. FEVi was measured after 
20 and 40 min, and UNDW provocations and FEVi measurements were performed 
after 10, 20 and 34 h.
Compared to placebo, salmeterol caused marked bronchodilatation from 20 min 
up to 20 h after inhalation. Salmeterol also provided more than 20 h of protection 
against UNDW provocation (still more than one doubling dose). Protection beyond 
the period of bronchodilatation did not occur. Eleven subjects had a significant 
reduction in provocative dose of UNDW causing a 20% fall in FEVi (PD20,undw) 
values between 10 and 20 h, at a time when there was still persistent bronchodi­
lation. No correlation existed between changes in FEVi and changes in PD20,undw. 
From the equations of regression lines between FEVi and corresponding PD20,undw 
values, it was calculated that only ~25% of the afforded protection was explained 
by bronchodilatation.
In conclusion, a single dose of salmeterol induces both bronchodilatation and 
protection independently of this bronchodilation against a physiological bron- 
choconstrictor stimulus for more than 20 h.
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The long-acting p2-agonist salmeterol xinafoate has a 
higher potency and much longer duration of action than 
the short-acting p2-agonists such as salbutamol [1]. 
Unlike the short-acting j32-agonists, it has been suggest­
ed that salmeterol has some anti-inflammatory proper­
ties. In vitro data showed that salmeterol blocked mast 
cell mediator release 10-35 times more potently than 
salbutamol, with effects persisting for more than 20 h 
[2], Salmeterol, but not salbutamol, also had inhibitory 
effects on other inflammatory cells such as eosinophils 
and alveolar macrophages [3], and afforded long-last­
ing inhibition of increases in vascular permeability [4]. 
Despite these cellular and vascular effects, evidence that 
they are of clinical relevance is still lacking. No change 
in bronchial hyperresponsiveness (BHR) was reported after 
6 weeks of treatment with salmeterol [5] and analysis of 
bronchoalveolar lavage (BAL) cell profile has not shown 
convincing evidence of an anti-inflammatory effect [6].
On the other hand, Twentyman et al. [7] suggested that 
salmeterol has some additional effects, Le. preventing 
the increase in BHR after allergen provocation, beyond
the tim e o f bronchodilation. Pedersen et a l  [8] also re­
ported that salmeterol blocked the late asthmatic resp­
onse and increase in BHR after allergen provocation.
In contrast to pharmacological stimuli such as histam­
ine and methacholine, ultrasonically nebulized distilled 
water (UNDW) induces airway narrowing indirectly, by 
causing the release of endogenous mediators and possi­
bly by initiating vagal reflex mechanisms [9, 10]. Chal­
lenge with UNDW may increase BHR and induce a late 
asthmatic response, in the same manner as allergen expo­
sure [10]. Thus, the mechanism by which UNDW provo­
cation induces bronchoconstriction is likely to be similar 
to those involved in asthma provoked by naturally occur­
ring stimuli [9]. If the above-mentioned long-lasting 
cell-stabilizing effect of salmeterol were present in vivo, 
this drug might be expected to afford prolonged pro­
tection against UNDW provocation.
The present study was, therefore, designed to assess 
whether a single dose of salmeterol provided long-last­
ing protection against UNDW provocation and whether 
or not this was caused by its bronchodilating properties.
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Materials and methods
Study design
This randomized, double-blind, placebo controlled, 
crossover trial consisted of two identical 3 day study 
periods, with a minimal interval of 1 week between the 
start of the two periods, in order to prevent any carry­
over effect. Subjects withheld rescue medication (salbu­
tamol 100 \xg by metered dose inhaler (MDI)) at least 
6 h before each visit and rested for at least 15 min before 
starting measurements.
On the first day, at 22.00 h, baseline forced expiratory 
volume in one second (FEVi) was measured. Subsequent­
ly, study medication was administered, consisting of two 
inhalations of 25 |ag of salmeterol or placebo by MDI 
in random order. Flow-volume curves were recorded 20 
and 40 min afterwards. On the second and third day, 
Le. 10 h (at 08.00 h), 20 h (at 18.00 h), and 34 h (08.00 
h the next day) after inhalation of the study medication, 
FEVi measurements and a UNDW provocation were 
performed. Baseline FEVi on the starting evening of 
both periods had to be within 10%, otherwise the sec­
ond period was postponed to a later day.
Subjects
Nineteen nonsmoking asthmatic patients (6 males, 13 
females) according to the criteria of the American Thoracic 
Society [11], aged 16-54 (mean 28) yrs, entered the 
study. Sixteen persons were atopic, defined by an ele­
vated specific immunoglobulin E or positive intracuta- 
neous tests against house dust mite or two of seven other 
tested common aero-allergens [12]. At study entry, FEVi 
had to be >50% predicted, and reversibility had to be 
>15% from prebronchodilator values in response to 200 
|j.g salbutamol by MDI. The provocative concentration 
of histamine causing a 20% fall in FEVi (PC20,h) [13] 
had to be below 4 mg-mL'1 for all subjects. None had 
any significant medical condition or an upper or lower 
respiratory tract infection within 6 weeks before the 
study. Seasonally allergic persons were not measured 
during the time when exposure to such allergen was like­
ly. During the study, the subjects used only salbutamol 
by MDI (100 jig) as needed to control symptoms. Anti­
inflammatory treatment (inhaled corticosteroids, nedo** 
cromil sodium, and cromolyn sodium) were withheld 
for at least 6 weeks preceding the study and systemic 
steroids for at least 6 months. Methylxanthines were 
stopped at least 48 h, anticholinergics and antihistam­
ines at least 24 h, before the start of the trial. The study 
was approved by the local hospital Ethics Committee; 
written informed consent was obtained from all partic­
ipants.
Methods
The bronchodilator response and reactions to UNDW 
provocation were assessed by FEVi, obtained from flow- 
volume curves recorded on a heated pneumotachograph
(Spiro analyser ST 250®; Fukuda Sangyo Co., Tokyo). 
Baseline FEVi was recorded from the best of three repro­
ducible values (within 5%).
The UNDW provocation test was performed accord­
ing to the method described by Groot et a l  [14]. An 
ultrasonic nebulizer (Ultraneb 99, DeVilbiss, Somerset, 
PA, USA) was used at a fixed output of 2.0Q±0.05 
mL-min-1. The patient inhaled UNDW during tidal brea­
thing through a mouthpiece with tightened lips and the 
nose clipped. A Wright respirometer (British Oxygen 
Co., London, UK) was connected to a two-way valve 
(Laerdal IV, Stavanger, Norway), placed in-between the 
aerosol hose and the mouthpiece, to measure the total 
volume of inhaled air. After inhalation of 20 L of ambi­
ent air through the system, doubling volumes of air with 
UNDW (3,5,10, up to 160 L) were successively inhaled 
at 5 min intervals. The response to inhaled UNDW was 
assessed by FEVi after 90 and 180 s of each dose. The 
test was stopped if FEVi dropped by at least 20% or if 
160 L of air with UNDW was inhaled. Before and after 
each test, the nebulizer chamber and aerosol hose were 
weighted. The cumulative dose of inhaled distilled water 
in mL H20  causing a 20% fall in FEVi from post-air 
values (PD20,UNDW), was calculated by linear interpo­
lation on a semilogarithmic curve.
Pretrial PC20,H was measured according to the method 
of Cockroft et al. [13]. In short, the patient inhaled 
doubling doses of histartiine phosphate from 0.03 to 16 
mg-mL-1. The test was stopped if FEVi fell 20% from 
baseline, and a log dose-response curve was construct­
ed. The PC20,H was calculated in mg-mL'1 by linear 
interpolation.
Sta tistical ana lysis
All PD20,UNDW data were logio transformed before 
analysis. FEVi data were expressed as % pred [15]. To 
calculate the treatment effect of salmeterol, differences 
between values (FEVi and PD20,UNDW) on salmeterol 
and on placebo were calculated and tested at each time- 
point with the Wilcoxon signed rank test. The change 
in UNDW responsiveness (APD20,UNDW) was expressed 
in doubling doses (DD), calculated as:
((logPD20,UNDW-salmeterol)-
(logPD20,UNDW-placebo))/log2
Period and carry-over effects were analysed accord­
ing to K och [16]. The coefficient of repeatability for 
PD20,UNDW was calculated for each subject using the 
two UNDW provocations in the placebo period (base­
line), at the same time of the day (08:00 h) according 
to the method of B lan d  and A ltm an  [17]. Correlations 
between variables were performed with the Spearman 
correlation test. Regression lines were compared with 
analysis of variance (A N OVA) of repeated measure­
ments. For multiple comparisons, a Bonferroni correc­
tion was used. A  p-value of 0.05 or less was considered 
significant for one test. For multiple comparisons, this 
boundary was set at 0.01. Data are reported as mean 
values (sem).
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Results Baseline FEVl and changes during study medication
Patient characteristics are listed in table 1. Seven­
teen patients completed the study. Two persons (sub­
jects No. 2 and 8) failed to return to the laboratory for 
lung function and provocation tests for the second 
treatment period (both after placebo in period one) and 
were withdrawn from the study. There were no period 
or carry-over effects between the two study periods at 
any time-point with regard to FEVl and PD20,undw 
data.
Baseline FEVl at 22.00 h on the starting day of both 
periods was similar with a variation of 1.8% (range 
0.3-9.7% pred).
Salmeterol caused a significant and substantial degree 
of bronchodilatation versus placebo from 20 min up to 
20 h after inhalation (per cent increase from baseline 
after salmeterol 14.8 (2.1), 17.7 (2.3), 13.9 (3.2) and 
12.7 (1.7) 1% after 20 and 40 min and 10 and 20 h, 
respectively; all time-points significantly different from 
placebo (pcO.OOl), except for 34 h (p=0.55)) (table 2).
Table 1. Characteristics of the study subjects
Subject
No.
Sex Age
yrs
Atopic FEVl 
% pred
Reversibility*
%
PC20,H
mg-mL'1
Médication*
1 M 33 Yes 8 5 2 15.1 0.33 B
2 F 23 Y es 95.0 15.6 0.09 B
3 M 26 Yes 99.6 17.4 0.36 B
4 M 25 Yes 64.0 24.5 1.09 B
5 F 18 Yes 56.2 317 0.08 B, T
6 M 39 Yes 85.6 18,5 0.71 B, C
7 F 42 No 59.0 26.9 0.07 B
8 F 26 Yes 99.7 15.6 0.15 B
9 F 16 Yes 106.3 15.6 0.10 B
10 M 22 Yes 77.6 26.1 0.62 B
11 F 27 Yes 96.3 19.2 0.15 B
12 F 22 No 99.7 15.1 1.05 B
13 F 26 Yes 100.3 27,9 0.25 B
14 F 23 Yes 90.3 197 0.90 B
15 M 18 Yes 60.2 46.4 0.07 A,B
16 F 54 No 103.3 30.9 1.98 B
17 F 31 Yes 76.4 16.7 3.62 B
18 F 27 Yes 84.9 187 0.25 B, IC
19 F 26 Yes 77.3 22.5 0.54 B, C
Mean
SEM
27.6
2.1
85.1
3.7
22.3
1.8
0.65
0.20
*: reversibility to salbutamol 200 fig by metered-dose inhaler (% change from prebroncho dilator value). +: therapy until 6 weeks
before participation in the study. PC20,H: provocative concentration of histamine causing a 20% fall in forced expiratory volume
in one second; A: anticholinergic; B: (32-agonist; C: cromolyn sodium; IC; inhaled corticosteroids; T: oral theophylline; M: male; 
F: female.
Table 2. Individual data of forced expiratory volume in one second (percentage of predicted vaiue)
Time after inhalation
Patient
No.
Baseline
20 min 40 min 10 h 20 h 34 h
SLM Placebo SLM Placebo SLM Placebo SLM Placebo SLM Placebo
1 84.5 103.1 84.3 105.6 87.2 93.1 81.1 92.8 82.8 82.8 80.6
3 106.0 115.8 104.9 119.0 108.0 113.6 106.0 113.4 116.0 98.4 103.0
4 55.1 63.2 56.6 67.3 60.9 63.8 44.1 607 56.4 54.3 44.6
5 54.2 64.3 56.4 67.9 53.4 46.0 38.9 64.6 55.3 57.8 60.5
6 85.0 91.0 86.4 96.2 85.8 95.1 73.1 88.4 89.9 75.2 81.2
7 49.0 53.5 50.9 53.5 51.2 59.7 50.9 66.4 50.9 52.7 50.5
9 109.4 119.4 108.0 120.2 109.1 121.7 112.8 117.1 115.7 117.1 113.4
10 76.7 95,0 73.8 98.6 77.3 95.8 71.2 99.0 80.9 88.8 66.6
11 95.6 114.5 99.6 112.3 101.8 124.3 100.9 108.0 100.6 99.0 100.3
12 94.6 100.5 94.0 107.0 82.1 98.3 70.8 108.2 79.8 63.4 73.6
13 68.8 105.5 60.0 104.3 58.3 106.1 62.9 90.9 72.3 68.8 83.0
14 94.9 111.1 94.4 111.7 100.0 111.1 90.3 111.9 102.5 100.2 92.8
15 61.2 75.4 65.1 82.5 60.6 86.0 56.5 75.2 49.8 46.2 46.4
16 87.7 118.7 80.2 123.9 81.6 102.3 89.6 104.2 89.6 84.0 86.3
17 81.2 92.6 81.8 94.2 83.4 92.9 80.8 92.3 85.0 81.5 78.2
18 90.6 98,1 83.7 97.2 86.1 100.6 78.6 94.8 83.1 82.5 54.2
19 93.8 97.3 90.2 95.8 91.4 97.0 90.2 92.9 93.5 86.1 81.4
Mean 81.7 95.2 80,6 97.5 81.1 94.5 76.4 93.0 82.6 78.7 76.3
SEM 4.4 4.9 4.3 4.8 4.5 5.1 5.1 4.2 5.0 4.7 4.9
SLM: salmeterol.
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The early morning dip seen after treatment with pla­
cebo (at 08.00 h) (mean change in FEVl -7,2%, range 
-28 to +5, compared to 22.00 h) was completely abol­
ished in all but one patient (p<0.001). The next morn­
ing (34 h after inhalation), salmeterol no longer provided 
protection against a morning dip.
UNDW provocation tests
Two of the 17 persons differed in their response to 
UNDW provocation from the others. Subject No, 1 
appeared to be unresponsive to UNDW provocation. He 
recovered very fast from the constrictor effects of UNDW 
and showed a plateau in reaction of FEVl at 80% of the 
post-air values. Subject No. 10 turned out to be refrac­
tory to subsequent UNDW provocation tests. PD20,UNDW 
increased at subsequent tests, and he ended totally unre­
sponsive at the third test (table 3). For these two patients, 
no real treatment effect of salmeterol could be calcu­
lated, but exclusion of their data did not alter the lev­
els of significance for the major outcome variables. The 
other 15 subjects demonstrated a good short-term repro­
ducibility of PD20,undw. The standard deviation of the 
differences for baseline UNDW provocations was 0.67 
DD.
In the whole group (n=17), treatment with salmeterol 
resulted in protection against UNDW-induced broncho- 
constriction for at least 20 h (table 3). Ten hours after 
the inhalation of salmeterol, a significant increase was 
observed in the PD20,UNDW of 16.7 (2.3) mL H20  as 
compared with 3.3 (1.4) mL H20 after placebo (treat­
ment effect of 2.82 (0.35) DD, p<0.0001). In nine of the 
17 subjects, the maximum dose of UNDW was reached. 
In these patients, the total amount of mL H20  inhaled
Table 3. -  Individual data of PD20
Time after inhalation
Patient 10 h 20 h 34 h
No.
SLM Placebo# SLM Placebo SLM Placebo#
1 19.3 25.0 6.1 10.9 11.2 21.2
3 15.4 2.6 2.7 4.8 1.3 1.9
4 1.7 0.9 1.3 1.2 1.7 1.3
5 1.0 0.3 1.9 0.4 0.2 0.5
6 18.5 6.3 10.6 7.6 10.0 6.5
7 21.7 0.7 6.7 1,8 2.2 2.8
9 19.9 0.9 4.7 1.0 2.7 1.3
10 30.1 1.7 25.6 6.1 27.3 31.2
11 12.2 3.4 7.7 3.0 2.1 3.8
12 23.1 1.9 3.2 2.2 2.7 1.9
13 12.9 0.9 1.9 0.9 0.8 1.3
14 17.5 1.7 17.3 5.7 5.3 2.1
15 8.9 1.0 1.7 1.0 2.0 1.0
16 11.9 2.4 4.0 1.5 3.74 2.9
17 8.3 1.8 10.7 3.2 1.2 2.0
18 37.2 1.6 6.8 1.4 1.9 0.8
19 23.2 1.6 5.6 2.8 5.4 2.7
Mean 16.7 3.3 7.0 3.3 4.8 5.0
SEM 2.3 1.4 1.5 0.7 1.6 2.0
SLM: salmeterol; PD20: provocative dose causing a 20% fall 
in forced expiratory volume in one second; data used for 
the coefficient of repeatability (excluded patients Nos. 1 and 
10; see text).
at that time was taken for analysis, since no PD20,UNDW 
could be reached after salmeterol. Twenty hours after 
inhalation (at 18.00 h) there was still a significant pro­
tection for UNDW, with a PD20,UNDW of 7.0 (1.5) mL 
H20  after salmeterol as compared with 3.3 (0.7) mL 
H20  after placebo (treatment effect of 1.09 (0.23) DD, 
p=0.0008). After 34 h (at 08.00 h) PD20}UNDW values 
returned to placebo level (4.8 (1.6) mLH20  after salme­
terol as compared with 5.0 (2.0) mL H20  after placebo 
(treatment effect of 0.1 (0,2) DD, p=0.55)).
Relationship between UNDW provocation and airway 
calibre
For each time-point, APD20,UNDW was not correlat­
ed with the corresponding change in FEVl (AFEVi) 
from placebo to salmeterol (all rc0 .ll, p>0.65).
Figure 1 shows the FEV1 and corresponding PD20,UND W 
values of the individual patients 10 and 20 h (fig. la), and 
20 and 34 h (fig. lb) after inhalation of salmeterol. From 
10 to 20 h, in most individual patients and as a group, 
FEVl did not change (p=0.38), while PD20,UNDW drop­
ped significantly (p=0.002, fig. lb). From 20 to 34 h, 
both mean FEVl and mean PD20,UNDW decreased sig­
nificantly (pcO.OOl and p=0.02, respectively), but again 
some individual patients showed (almost) no decrease 
in FEVl, while PD20,UNDW dropped (lines appear rough­
ly vertical), while other patients exhibited a decrease in 
FEVl with no change in PD20, (lines are more or less 
horizontal). Both time courses indicate that the protec­
tion afforded by salmeterol was independent from bron- 
chodilation.
The slopes of the regression lines through these points 
after 10 and 20, but not after 34 h on salmeterol and 
placebo differed significantly from zero (p~0.001 and 
p=0.03, respectively), indicating a (linear) relationship 
between starting airway calibre and BHR. The slopes 
between the regression lines of salmeterol in compari­
son with placebo were not different at any time-point 
(all p>0.49), but again, both after 10 and 20 h, the treat­
ment effect of salmeterol was highly significant, plac­
ing the lines after salmeterol parallel at a higher level 
compared to placebo (p=0.000 and p=0.002, respec­
tively), Previously, it has been shown that there is a lin­
ear relationship between FEVl and the provocative 
concentration of methacholine causing a 20% fall in 
FEVl (PC20,m) [18]. Under the assumption of a simi­
lar relationship between FEVl and PD20,UNDW and 
because the measurements on salmeterol and on place­
bo are paired, the relationship between PD20,UNDW, and 
FEVl can be describe statistically with one equation for 
the regression lines at each time-point:
after 10 h: PD 20/UNDW = -0.747 + 1.075 treatment +
0.035xFEVl
after 20 h: PD20,UNDW = -0.636 + 0.408 treatment +
0.028xFEVl
where treatment is assigned a value of +1 for salme­
terol and -1 for placebo.
APD20,UNDW is 2.8 and 1.1 DD, and AFEVi is 18.4% 
and 10.4%, after 10 and 20 h, respectively. It follows 
from the equation that 10 h after inhaling salmeterol,
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Fig. 1. -  The change in FEVl and corresponding PD20>u n d w  points in each patient, from: a) 10-20 h; and b) 20-34 h after inhalation of sal­
meterol. □: 10 h; ■: 20 h; A: 34 h after inhalation of salmeterol, Mean (sem) values of FEVl and PD 20,undw  are shown at the corresponding 
axes: *: p<0.05; **: p<0.01; ***: pcO.OOl; ns: nonsignificant. FEVi: forced expiratory volume in one second; P D 20,undw : provocative dose of 
ultrasonically nebulized distilled water causing a 20% fall of FEVl; % pred: percentage of predicted value.
the treatment effect is +2.15 DD and the effect through 
FEVl is 0.035x18.4=0.65, hence 2.8 DD as found in 
the study. After 20 h, the treatment effect is +0.82 and 
the effect through FEVl is 0.028x10.4=0.29 (hence the 
real found protection of 1.1 DD). This means that only 
23% (0.65/2.80x100%) of the afforded protection can 
be explained by bronchodilation, and 77% by a direct 
effect of salmeterol. After 20 h these values are 26 and 
74%, respectively.
Discussion
This study shows that a single dose of salmeterol aff­
ords both bronchodilation and protection against UNDW 
provocation up to 20 h in asthmatic patients who did 
not use anti-inflammatory medication. Protection against 
UNDW provocation beyond the period of bronchodila­
tion did not occur. In 11 of 17 patients, the inhibition 
of bronchoconstriction to UNDW decreased significantly 
between 10 and 20 h, at which time bronchodilation 
persisted. However, protection was still more than 1 DD 
after 20 h, and up to this time, only a maximum of 26% 
of the protection could be explained by the bronchodi- 
lating effect of salmeterol.
The duration of protection against UNDW challenge 
was in line with the in vitro activity of salmeterol. 
UNDW provocation is thought to be mediated by the 
release of mast cell mediators [9,10]. Salmeterol inhibits 
the release of these mediators from sensitized human 
lung fragments for more than 20 h [2]. In the present 
study, a single dose of salmeterol afforded protection at 
10 h of almost 3 DD, and, although the magnitude of 
the protection weaned, protection was still more than 1 
DD after 20 h. In this way, salmeterol showed, in vivo, 
a relevant protection during the period of blocking medi­
ators in vitro [2].
In accordance with B o o t h  et a l [19], no increase in 
BHR after withdrawal of salmeterol was found in our 
study. Thirty four hours after inhalation of salmeterol 
(more than three times the half-life), no rebound BHR 
to UNDW occurred, the P D 20,UNDW being 0.12 DD 
above placebo.
Salmeterol also induced bronchodilation for more 
than 20 h, and protected against the early morning dip 
10 h after inhalation. T w e n ty m a n  et a l [7] tested bron­
chodilation of a single dose of salmeterol up to 34 h, 
but regular measurements were discontinued after 9.5 
h. When starting measurements again after 32 h, sal­
meterol no longer afforded bronchodilation. In a group 
of asthmatic patients with similar characteristics as in 
the present study, R ab e et a l [20] showed that salme- 
terol decreased airway tone significantly over a whole 
24 h period, compared with placebo. Because of multi­
ple comparisons, however, the bronchodilating effect 
was not significant beyond 12 h at the individual time- 
points. Our study clearly shows a bronchodilation up to 
20 h, which disappeared after 34 h.
Besides bronchodilation, an important property of 
salmeterol could be the ability to afford protection of 
airways smooth muscle against bronchoconstrictor med­
iators with time-course characteristics different from 
those observed for bronchodilation [7]. Since baseline 
airway function correlates somewhat with airway reac­
tivity [18], the inhibitory effect of a bronchodilator could 
be due to a change in airway calibre. In this study, both 
bronchodilation and protection lasted more than 20 h 
but less than 34 h. More measurements of UNDW provo­
cation during this period would be needed to determine 
exactly the duration of action and to distinguish bet­
ween protection and bronchodilation. However, we made 
measurements at 10 h intervals to avoid confounding 
problems such as a temporary (small) increase in BHR 
after UNDW provocation [10, 21], and to avoid refrac­
toriness after repeated UNDW measurements [14, 21], 
which may persist up to 4 h after the last challenge [22, 
23]. Despite this, two patients (subjects No. 2 (dropped 
out) and 10) became refractory to successive UNDW 
provocations.
No correlation was found between bronchodilation 
(A FEV i) and protection (APD20,UNDW) provided by sal­
meterol at any time-point, indicating that protection was 
not caused by bronchodilation. However, the number of 
patients in our study is probably too small to state that 
there might not be a correlation with a much larger
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population. On the other hand, figure 1 shows that in 
individual patients the protection afforded by salmeterol 
is independent of airway calibre, and there were mod- 
erate-to-severe responses to inhalation to water at a 
time when airway calibre was optimal. The regression 
lines through these points again show a highly signifi­
cant treatment effect of salmeterol, by shifting the lines 
at 10 and 20 h parallel to higher levels than after place­
bo. From the equations of the regression lines on sal­
meterol and on placebo at the various time-points, it can 
be calculated that up to 20 h, only a maximum of 26% 
of the protection can be explained by the bronchodilat- 
ing effect of salmeterol. Therefore, there seems to be a 
differential effect of salmeterol on lung function and the 
response to UNDW, A similar dissociation has been 
shown with sodium cromoglycate, which had no effect 
on lung function, but did block UNDW provocation 
[24]. Conversely, ipratropium bromide in doses up to 
160 jLxg caused bronchodilation, but did not change the 
response to challenge with UNDW [25].
Other mechanisms are thus likely to be involved in 
the protective effects of salmeterol against UNDW-in- 
duced bronchoconstriction. The term functional antago­
nism is often used to describe the protective effects of 
P2-agonists during provocation tests. P2-agonists maY 
prevent smooth muscle contraction, irrespective of the 
constrictor mediator, by acting on a different receptor 
on the same cell, which opposes this constriction [26]. 
In this way, pharmacological effects of p2-agonists are 
different between smooth muscle relaxation and pro­
tection against bronchoconstriction [27]. It has previ­
ously been shown that p2-agonists provide true functional 
antagonistic protection at the level of the smooth mus­
cle against direct pharmacological stimuli as histamine 
and methacholine [28]. UNDW, however, is thought not 
to act directly at the level of the smooth muscle, but to 
induce airway narrowing indirectly [9, 10]. Therefore, 
mechanisms other than bronchodilation and functional 
antagonism should be considered to explain this appar­
ent dissociation.
O’Connor et a l [29] showed that P2-agonists have an 
additional inhibitory nonsmooth muscle effect on bron- 
choconstrictor stimuli that involve mast cell activation, 
in affording a greater protection against adenosine mono­
phosphate- than methacholine-induced bronchoconstri­
ction. Salmeterol has several acute anti-inflammatory 
effects in vitro that may contribute, e.g. the strong inhi­
bition of the release of mast cell mediators [2], involved 
in the mechanism of action of UNDW. Thus, although 
the evidence is only indirect, this protection may indi­
cate long-lasting cell-stabilizing effects of salmeterol in 
vivo up to 20 h rather than functional antagonism.
Finally, in a number of patients, the protection of sal­
meterol against UNDW decreased, while bronchodila­
tion persisted. This dichotomy between duration of 
bronchodilation and protection against a bronchocon- 
strictor stimulus has already been described by A hrens 
et a l [30]. These differences in time course could reflect 
differences in the mechanism for these two p2-agonis- 
tic actions. However, an alternative explanation could 
be the differences in potency of the bronchoconstrictor 
stimulus. A  larger concentration of a p2-agonist may be 
required to prevent contraction to a potent stimulus as 
a provocation test, as compared with the concentration
of the drug to produce relaxation of the relatively mod­
est level of bronchospasm at baseline [31]. Several stud­
ies showed a relationship between bronchodilator dose 
and the degree of inhibition of provocation [32]. A 
greater concentration of salmeterol may be required to 
prevent contraction to UNDW provocation than is required 
to produce relaxation. However, the concentration of 
salmeterol required to prevent mast cell mediator release 
may similarly be higher than the concentration required 
to prevent contraction of the muscle by the mediators 
released.
Whether this nonbronchodilator effect of salmeterol 
also provides clinically relevant effects or persists after 
prolonged therapy, is at present unclear. No change in 
BHR was reported after 6 weeks of treatment with sal­
meterol [7]. On the other hand, salmeterol significantly 
improved the treatment of (chronic) bronchial asthma 
and resulted in a clinical significant improvement in qual­
ity of life versus placebo and salbutamol [33], G r e e n in g  
et a l  [34] showed that adding salmeterol to inhaled cor­
ticosteroid therapy was more appropriate for patients 
with inadequately controlled asthma on low-dose inhaled 
corticosteroids than doubling this dose. Finally, in this 
study, salmeterol afforded a significant protection of 
more thaii 20 h against a naturally occurring stimulus, 
which may be very relevant for asthma management.
In conclusion, our study shows that a single dose of 
salmeterol in mild-to-moderate asthma causes bron­
chodilation and protection independently of this bron­
chodilation against a physiological bronchoconstrictor 
stimulus for more than 20 h.
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